StockTipsArenaBeta

BUY SYMBIOTEC PHARMALAB LTD — JM Financial

BUYSYMBIOTEC PHARMALAB LTD
SYMBIOTEC PHARMALAB share price target & all analyst calls

byJM FinancialHorizon: NA (inferred 1 year)27 Oct 2026via LiveMint Markets

Entry₹1,285.9Inferred
Target₹1,622
Total upside +26.14%
Stop lossNot given
CMP₹1,262.9Just now
Active-1.79%+28.43%upside left 12 mo left
Follow JM Financial for new calls(94% target hit, 16 closed calls)Get alertsWatch SYMBIOTEC for new buy/sell callsGet alertsSee 2 other Long-term calls on SYMBIOTECSee 244 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 29 Oct, 11:45 am IST
5 supporting5 neutral0 opposing
Supports the BUY call (5)

Symbiotec Pharmalab Gets Motilal Oswal's 'Buy' Initiation; Check Target Price

NewsNdtv-Profit·26 Oct · 3d ago

(opens in new tab)

2 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · 3d ago

Broker’s call: Symbiotec Pharmalab (Buy)

NewsHbl·1 Oct · 4w ago

(opens in new tab)

Symbiotec's subsidiary, Knovea Pharmaceutical, signed a strategic commercialization agreement with a global pharmaceutical company for Dual Chamber Vials.

BSE · Company Update·30 Sept · 4w ago

(opens in new tab)

Symbiotec Pharma shares jump 8% after US FDA report on Pithampur plant

NewsCnbc-Tv18·29 Sept · 4w ago

(opens in new tab)
Neutral / worth noting (5)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on SYMBIOTEC PHARMALAB

All analyst calls on SYMBIOTEC PHARMALAB

More from JM Financial

Every call and its outcome